No Data
Rodman & Renshaw Initiates Coverage On BioXcel Therapeutics With Buy Rating, Announces Price Target of $65
BioXcel Therapeutics Analyst Ratings
BioXcel Therapeutics Bolsters Cash Reserves To Advance SERENITY At-Home Phase 3 Trial, Topline Data Expected In H2 2025
BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated With Bipolar Disorders or Schizophrenia
Why BioXcel Therapeutics, Inc. (BTAI) Soared Last Week
BioXcel Therapeutics Climbs After Enrollment Update in Drug Trial
Buck15 : they haven’t meet the required 30 million which is tomorrow, they will be delisted tomorrow, as I have yet to see news they are compliant
71735916 : they plan to dispute, which will stop delisting until the hearing. keep an eye on hearing date and sell before because this shit is going eventually